solute carrier family 19 member 2Genealiases: TC1 · THMD1 · THT1 · THTR1 · TRMA
Q-omics provides the consensus-scored SLC19A2 profile across patient tissues and cancer cell-line models. SLC19A2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SLC19A2 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, SLC19A2 RNA expression shows 19,773 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KIRC, and UVM as cancer lineages where SLC19A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC19A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC19A2 survival associations across molecular data types. SLC19A2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC19A2 RNA expression–survival associations across cancer types. High SLC19A2 expression shows unfavorable associations in MESO, UVM, STAD and DLBC, but favorable associations in BRCA and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for SLC19A2 RNA expression.
This table summarizes SLC19A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC19A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC19A2 shows lower tumor expression in KIRC, THCA and LUSC and higher tumor expression in COAD, BRCA and READ. The KIRC box plot shows higher SLC19A2 RNA expression in normal versus tumor tissue (log2 FC = −1.666, t-test p < 0.001).
This table shows molecular features associated with SLC19A2 in patient tissues and cancer cell lines. In patient samples, SLC19A2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC19A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
